robert lustig glp 1 agonist may interfere with the body’s reward system 14 - Robert Lustig, M.D.,

Despite the potential clinical benefits of GLP-1RA plus SGLT2i combination therapy in patients with T2DM, several factors may delay this combination to become a common practice soon, such as reimbursement and costs associated with polypharmacy

Heres whats going on, what it means for you and what to do next.

Learn how Ozempic, Wegovy, and similar drugs may affect SIBO, IMO, IBS symptoms, and the gut microbiome.

Learn how semaglutide and liraglutide support weight loss, NHS eligibility, and how to optimise your results.

Sign up for a GLP-1 program and receive 3 months of B12 injections FREE

Learn more: read our full guide to microdosing tirzepatide and the GLP-1 microdosing chart